Post Marketing Surveillance on Long Term Drug Use of Trazenta Tablets in Patients With Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Linagliptin (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 14 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.
- 14 Feb 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
- 20 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.